Tokyo, Japan

Yuuichi Sugimoto

USPTO Granted Patents = 10 


 

Average Co-Inventor Count = 2.3

ph-index = 4

Forward Citations = 59(Granted Patents)


Company Filing History:


Years Active: 2013-2018

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Yuuichi Sugimoto: Innovator in Pharmaceutical Chemistry

Introduction

Yuuichi Sugimoto is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds with anti-tumor activity. With a total of 10 patents to his name, Sugimoto's work is recognized for its potential impact on cancer treatment.

Latest Patents

Among his latest patents, Sugimoto has developed crystals of dispiropyrrolidine derivatives. These crystals include a dispiropyrrolidine compound or a salt thereof that inhibits the action of Mdm2. The invention provides crystals of a specific compound that has demonstrated anti-tumor activity. This compound is characterized by its complex chemical structure, which includes various functional groups that enhance its efficacy as a medicament.

Career Highlights

Yuuichi Sugimoto is currently associated with Daiichi Sankyo Company, Limited, where he continues to innovate in the pharmaceutical sector. His research focuses on creating effective treatments for cancer, leveraging his expertise in chemical compounds and their biological interactions.

Collaborations

Sugimoto has collaborated with notable colleagues in his field, including Shoko Yoshida and Kouichi Uoto. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical solutions.

Conclusion

Yuuichi Sugimoto's contributions to pharmaceutical chemistry, particularly through his innovative patents, highlight his role as a key inventor in the fight against cancer. His work continues to inspire advancements in medical treatments and showcases the importance of research in improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…